AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 JUN 13 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - The inability of tumor-infiltrating lymphocytes (TILs) to reach pancreatic tumor cells, and their loss of CD3 zeta, limits their potency against pancreatic cancer, say researchers working in Germany.
W. von Bernstorff and colleagues studied the immune mechanisms behind the dismal prognosis associated with pancreatic ductal adenocarcinoma by studying three parameters of disease activity: the secretion of immunosuppressive cytokines, the movement of TILs, and the loss of the signal transducing CD3 zeta chain of TILs.
Their study of 116 patients showed much higher levels of interleukin (IL)-10 and transforming growth factor (TGF)-beta 1/2 compared with controls.
TILs, having become trapped in the peritumoral tissue, were unable to reach tumor cells in significant numbers in 28 of 33 surgical specimens, the researchers reported.
"We suggest this is a simple but highly effective tumor escape mechanism," said von Bernstorff and coworkers ("Systemic and local immunosuppression in pancreatic cancer patients," Clin Cancer Res, 2001;7(3 Suppl):925S-932S).
Even when they did make contact, CD3 zeta was lost in most specimens (27 of 33 surgical specimens, nine of 19 peritumoral lymph nodes, and 13 of 25 peritoneal lavage specimens).